| [1] deRijk M C, Tzourio C, Breteler M M, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 1997, 62(1):10-15.[2] Marek K, Jennings D. Can we image premotor Parkinson disease?[J]. Neurology, 2009, 72(Suppl 7):21-26.[3] Leenders K L, Salmon E P, Tyrrell P, et al. The nigrostriatal dopa-minergic system assessed in vivo by positron emission tomography in healthy volunteer subject s and patients with Parkinson' s disease[J]. Arch Neurol, 1990, 47(12):1290-1298.[4] Braak H, deVos R A, Bohl J, et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plex-uses in cases staged for Parkinson's disease-related brain pathology[J]. Neurosci Lett, 2006, 396(1):67-72.[5] Abbott R D, Petrovitch H, White L R, et al. Frequency of bowel movements and the future risk of Parkinson' s disease[J]. Neurology, 2001, 57(3):456-462.[6] Claassen D O, Josephs K A, Ahlskog J E, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century[J]. Neurology, 2010, 75(6):494-499.[7] Liu Y, Qiang M, Wei Y, et al. A novel molecular mechanism for nitrated α-synuclein-induced cell death[J]. J Mol Cell Biol, 2011, 3(4):239-249.[8] Stemberger S, Poewe W, Wenning G K, et al. Targeted over expression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure[J]. Exp Neurol, 2010, 224(2):459-464.[9] Jones M L. Longevity of captive mammals[J]. Zool Garten, 1982, 52:113-128.[10] Robine J M, Allard M. The oldest human[J]. Science, 1998, 279(5358):1834-1835.[11] Fujiwara H, Hasegawa M, Dohmae N, et al. α-Synuclein is phosphorylated in synucleinopathy lesions[J]. Nat Cell Biol, 2002, 4:160-164.[12] Mbefo M K, Paleologou K E, Boucharaba A, et al. Phosphorylation of α-synucleins by members of the Polo-like kinase family[J]. J Biol Chem, 2010, 285(4):2807-2822.[13] Giasson B I, Duda J E, Murray I V, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions[J]. Science, 2000, 290(5493):985-989.[14] Hodara R, Norris E H, Giasson B I, et al. Functional consequences of α-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation[J]. J Biol Chem, 2004, 279(46):47746-47753.[15] Paleologou K E, Schmid A W, Rospigliosi C C, K et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of α-synuclein[J]. J Biol Chem, 2008, 283(24):16895-16905.[16] Kirkitadze M D, Bitan G, Teplow D B. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies[J]. J Neurosci Res, 2002, 69(5):567-577.[17] Yu S, Li X, Liu G, et al. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody[J]. Neuroscience, 2007, 145(2):539-555.[18] Li W, Lesuisse C, Xu Y, et al. Stabilization of α-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation[J]. J Neurosci, 2004, 24(33):7400-7409.[19] Chu Y, Kordower J H. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?[J]. Neurobiology Dis, 2007, 25(1):134-149.[20] Xuan Q, Xu S L, Lu D H, et al. Increase expression of α-synuclein in aged human brain associated with neuromelanin accumulation[J]. J Neural Transm, 2011, 118(11):1575-1583. |
